cagrilintide novo nordisk Data on experimental weight-loss drug show mostly mild side effects Novo Nordisk shares slide despite
Novo Nordisk shares slide despite promising weight loss trial results Obesity drug candidate Cagrilintide begins late stage program at Novo Nordisk Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial BioSpace 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or
Pay in 4 interest-free payments of $6.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16

